Oral toxicity of vigabatrin in immature rats: Characterization of intramyelinic edema

NeuroToxicology

Volumn 32, Issue 6, 2011, Pages 963-974

  Walzer, Mark ^a   Bekersky, Ihor ^a   Wanaski, Stephen ^a   Collins, Stephen ^a   Jortner, Bernard ^b   Patterson, Reid ^c   Garman, Robert ^d   Sagar, Stephen ^a   Tolbert, Dwain ^a  

^a LUNDBECK RESEARCH USA   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^c Reid Patterson Consulting Inc   (United States)

^d Veterinary Pathology Inc   (United States)

Author keywords

Animal studies; Drug toxicity; Intramyelinic edema; Toxicology; Vigabatrin

Indexed keywords

VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN DEPTH STIMULATION; BRAIN EDEMA; CELL VACUOLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ELECTRORETINOGRAPHY; FEMALE; FOOD INTAKE; GROWTH RETARDATION; INTRAMYELINIC EDEMA; MALE; MOTOR ACTIVITY; MYELIN SHEATH; MYELINATION; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RAT; SEXUAL MATURATION; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; WEIGHT GAIN;

ADMINISTRATION, ORAL; AGE FACTORS; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; EDEMA; FEMALE; GABA AGENTS; MALE; MOTOR ACTIVITY; MYELIN SHEATH; RATS; RATS, SPRAGUE-DAWLEY; RISK ASSESSMENT; TIME FACTORS; TOXICITY TESTS; VIGABATRIN;

ANIMALIA; RATTUS;

EID: 80055090937     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.03.014     Document Type: Article

References (44)

1. Appleton R.E., Peters A.C., Mumford J.P., Shaw D.E. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999, 40:1627-1633.
2. Arezzo J.C., Schroeder C.E., Litwak M.S., Steward D.L. Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol 1999, 27(Suppl. 1):53S-60S.
3. Ballard T.M., Knoflach F., Prinssen E., Borroni E., Vivian J.A., Basile J., et al. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) 2009, 202(1-3):207-223.
4. Butler W.H. The neuropathology of vigabatrin. Epilepsia 1989, 30(Suppl. 3):S15-S17.
5. Butler W.H., Ford G.P., Newberne J.W. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 1987, 15:143-148.
6. Cannon D.J., Butler W.H., Mumford J.P., Lewis P.J. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol 1991, 6(Suppl. 2):S17-S24.
7. Chapman D.P., Giles W.H. Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances. South Med J 1997, 90:471-480.
8. Chiron C., Dumas C., Jambaque I., Mumford J., Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997, 26:389-395.
9. Chiron C., Dulac O., Beaumont D., Palacios L., Pajot N., Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991, 6(2 Suppl.):S52-S59.
10. Cohen J.A., Fisher R.S., Brigell M.G., Peyster R.G., Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 2000, 41:148-157.
11. Dean C., Mosier M., Penry K. Dose-response stud of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999, 40:74-82.
12. Desguerre I., Marti I., Valayannopoulos V., Bahi-Buisson N., Dulac O., Plouin P., et al. Transient magnetic resonance diffusion abnormalities in west syndrome: the radiological expression of non-convulsive status epilepticus?. Dev Med Child Neurol 2008, 50:112-116.
13. Elterman R.D., Shields W.D., Mansfield K.A., Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001, 57:1416-1421.
14. French J.A. Vigabatrin. Epilepsia 1999, 40(Suppl. 5):S11-S16.
15. French J.A., Mosier M., Walker S., Sommerville K., Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled partial seizures. Neurology 1996, 46:54-61.
16. Gibson J.P., Yarrington J.T., Loudy D.E., Gerbig C.G., Hurst G.H., Newberne J.W. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990, 18:225-238.
17. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989, 27(Suppl. 1):43S-45S.
18. Haggerty G. Development of tier 1 neurobehavioral testing capabilities for incorporation into pivotal rodent safety assessment studies. J Am Coll Toxicol 1989, 8:53-69.
19. Hauw J.J., Trottier S., Boutry J.M., Sun P., Sazdovitch V., Duyckaerts C. The neuropathology of vigabatrin. Br J Clin Pract Suppl 1998, 61:10-13.
20. Holehan A.M., Merry B.J. Lifetime breeding studies in fully fed and dietary restricted female CFY Sprague-Dawley rats. 1. Effect of age, housing conditions and diet on fecundity. Mech Ageing Dev 1985, 33:19-28.
21. Horton M., Rafay M., Del Bigio M.R. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J Child Neurol 2009, 24:1543-1546.
22. Irwin S. Comprehensive observational assessment. Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968, 13:222-257.
23. Jackson G.D., Williams S.R., Weller R.O., van Bruggen N., Preece N.E., Williams S.C., et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 1994, 18:57-66.
24. John R.A., Rimmer E.M., Williams J., Cole G., Fowler L.J., Richens A. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin. Biochem Pharmacol 1987, 36:1467-1473.
25. Krauss G.L., Johnson M.A., Miller N.R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998, 50:614-618.
26. Loiseau P., Hardenberg J.P., Pestre M., Guyot M., Schechter P.J., Tell G.P. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 1986, 27:115-120.
27. Martin L.J., Bonin R.P., Orser B.A. Biochem Soc Trans 2009, 37(Pt 6):1334-1337.
28. McGaugh J.L. Memory consolidation and the amygdala: a systems perspective. Trends Neurosci 2002, 25:456-461.
29. Morris R. Spatial localization does not require the presence of local cues. Learn Mem 1981, 12:239-260.
30. Moser V. Screening approaches to neurotoxicity: a functional observational battery. J Am Coll Toxicol 1989, 8:85-93.
31. O'Donoghue J. Screening for neurotoxicity using a neurologically based examination and neuropathology. J Am Coll Toxicol 1989, 8:97-115.
32. Pearl P.L., Vezina L.G., Saneto R.P., McCarter R., Molloy-Wells E., Heffron A., et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009, 50:184-194.
33. Peyster R.G., Sussman N.M., Hershey B.L., Heydorn W.E., Meyerson L.R., Yarrington J.T., et al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 1995, 36:93-100.
34. Preece N.E., Houseman J., King M.D., Weller R.O., Williams S.R.S.R. Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry. Synapse 2004, 53:36-43.
35. Sabers A., Gram L. Pharmacology of vigabatrin. Pharmacol Toxicol 1992, 70:237-243.
36. Sabril (vigabatrin) prescribing information. Deerfield, IL: Lundbeck Inc; 2010.
37. Schroeder C.E., Gibson J.P., Yarrington J., Heydorn W.E., Sussman N.M., Arezzo J.C. Effects of high-dose gamma-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs. Epilepsia 1992, 33(Suppl. 5):S13-S25.
38. Spence S.J., Sankar R. Visual field defects and other ophthalmological disturbances associated with vigabatrin. Drug Saf 2001, 24:385-404.
39. Vanhatalo S., Nousiainen I., Eriksson K., Rantala H., Vainionpaa L., Mustonen K., et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002, 43:748-756.
40. Vigevano F., Cilio M.R. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997, 38:1270-1274.
41. Wecker J.R., Ison J.R., Foss J.A. Reflex modification as a test for sensory function. Neurobehav Toxicol Teratol 1985, 7:733-738.
42. Weiss K.L., Schroeder C.E., Kastin S.J., Gibson J.P., Yarrington J.T., Heydorn W.E., et al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology 1994, 44:1944-1949.
43. Willmore L.J., Abelson M.B., Ben-Menachem E., Pellock J.M., Shields W.D. Vigabatrin: 2008 update. Epilepsia 2009, 50:163-173.
44. Yarrington J.T., Gibson J.P., Dillberger J.E., Hurst G., Lippert B., Sussman N.M., et al. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1993, 21:480-489.